After successfully ‘saving’ two babies with terminal-stage acute Leukemia, Cellectis finally treated the first patient in its Phase I trial. A major milestone that could confirm the potential of its lead candidate UCART-19.
It’s once again a success for the French biotech company! As it announced on Monday, the first patient has been treated in the Phase 1 Trial of UCART19 in Pediatric Acute B lymphoblastic Leukemia (B-ALL). This study is taking place at the University College of London (UCL), where two previous babies have already been treated. The safety and efficiency are assessed during this trial.
But this treatment does not come alone!! It is performed ahead of planned allogeneic hematopoietic stem cell transplantation (allo-HSCT). Keep in mind that we never treat cancer with a single treatment, even if this treatment seems miraculous. It still requires parallel strategies. As Cellectis’ CEO said in our exclusive interview: ‘CAR-T is not the miracle cure for cancer.